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Objective. To evaluate the association between abscess size and duration of hospitalization and need for surgical intervention.
Methods. We collected data from patients admitted with ICD-9 codes 614.9 (PID) and 614.2 (TOA) from January 1, 1999—
December 31, 2005. We abstracted data regarding demographics, diagnostic testing/laboratory testing, imaging, treatment,
and clinical course. Two abscess groups were created: ≤8 cm or >8 cm. Descriptive statistics were calculated, and duration of
hospitalization and surgical intervention for women with large abscesses were compared to women with smaller collections.
Results. Of the 373 charts reviewed, 135 had a TOA and 31% required management with drainage and/or surgery. The average
abscess size for those treated successfully with conservative management was 6.3 cm versus those requiring drainage and/or surgery
(7.7 cm, P = .02). Every 1 cm increase in abscess size as associated with an increase in hospitalization by 0.4 days (P = .001).
Abscesses greater than 8 cm were associated with an increased risk of complications (P < .01). Conclusions. Larger tubo-ovarian
abscesses are associated with an increased duration of hospitalization and more complications including an increased need for
drainage or surgery. Additional research to determine the most eﬃcacious antibiotic regimen management strategy is needed.

1. Introduction
Tuboovarian abscess (TOA), typically the end result of
acute pelvic inflammatory disease (PID), is a condition
characterized by a walled-oﬀ inflammatory mass in the
pelvis. One-third to one-half of patients diagnosed with a
TOA acknowledge a history of PID [1, 2]. PID and TOAs are
polymicrobial infections of anaerobic and aerobic bacteria.
While Neisseria gonorrhoeae and Chlamydia trachomatis are
thought to facilitate the infection, they are rarely recovered
from an abscess [3, 4]. The most commonly isolated
organisms from TOAs are Escherichia coli and Bacteroides
species [5].
TOA is a complication of PID in 15% of cases, and 33%
of patients with PID requiring admission have a TOA [5].
Mortality associated with TOA has decreased dramatically
over the last 50 years. However, the morbidity associated
with TOA remains significant with complications including
infertility, ectopic pregnancy, chronic pelvic pain, pelvic
thrombophlebitis, and ovarian vein thrombosis [6].

While the majority of TOA respond to antibiotic therapy,
in approximately 25% of cases surgery or drainage is indicated [7]. There is some evidence that TOA size is associated
with need for intervention. Reed et al. in 1991 showed that
35% of abscesses 7 to 9 cm required surgery and nearly 60%
of abscesses ≥10 cm required surgery [8]. The objective of
our study was to assess the association of TOA size and
need for prolonged hospitalization and surgical intervention.
Our hypothesis was that TOA size would be associated with
prolonged hospitalization and increased need for surgery or
drainage.

2. Methods
After obtaining approval from the Washington University in
St. Louis Human Research Protection Oﬃce, we performed
a retrospective review of women diagnosed with TOA
admitted to Barnes-Jewish Hospital in Saint Louis, Missouri,
from January 1, 1999 until December 31, 2005. Potential
subjects were selected by the following ICD-9 codes: PID
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Table 1: History and sociodemographic characteristics of study
population.
Sociodemographic characteristics
Age
17–19 years
20–29 years
30–39 years
40 years or older
Race/ethnicity
White
Black
Hispanic/other
Smoking history
Yes
No
Unknown
Reproductive history
Gravidity
0
1-2
3 or more
Missing
Parity
0
1-2
3 or more
Missing
History of GC/CT
Any contraceptive use
Condom use
Tubal ligation

Table 2: Clinical characteristics by presence of TOA.

N (%)
10 (7%)
30 (22%)
51 (38%)
44 (33%)
37 (27%)
92 (68%)
6 (4%)
64 (47%)
45 (33%)
20 (19%)

28 (21%)
65 (48%)
39 (29%)
3 (2%)
44 (33%)
54 (40%)
32 (24%)
5 (4%)
38 (28%)
27 (20%)
10 (7%)
14 (10%)

(614.9) and TOA (614.2). Three hundred seventy-three
charts were then reviewed to confirm eligibility. Inclusion
criteria included (1) presence of an inflammatory mass in
the pelvis, (2) age greater than 17 years, and (3) admission to
Barnes-Jewish Hospital. We excluded charts of women who
did not have an inflammatory mass identified. Data were
abstracted for demographics, diagnostic testing, imaging,
treatment, and clinical course.
Imaging was obtained in almost all cases and included
ultrasound, CT, or MRI. In just over half of cases more than
one imaging modality was used. One abscess that was not
imaged preoperatively was identified at laparotomy. Fever
was defined as a temperature greater than 38.2◦ C. Complications were defined as factors that could result in prolonged
hospitalization; specifically, complications included intensive
care unit (ICU) admission, bowel or bladder injury, blood
transfusion, blood loss >1000 mL, sepsis or bacteremia,
ileus, readmission, and death. Data were abstracted by three
trained abstractors.
We created two abscess groups based on maximal diameter of the abscess: ≤8 cm and >8 cm. If bilateral abscesses
were noted, we used the larger of the two to quantify the

Clinical Characteristics
Reason presenting for care
Pain
Median duration of pain
Abnormal bleeding
Abnormal discharge
Information at admission
Fever
Pain
Vaginal discharge
Rebound
Guarding
Uterine tenderness
Adnexal tenderness
Cervical motion tenderness
Cervical culture
GC (n = 91)
CT (n = 91)
CT performed
US performed
MRI performed
WBC, mean (SD)∗∗
WBC
<10
10 to <15
15+
Unilateral abscess†
Largest abscess size (cm),
mean (SD) (Note: range = 1.5–16 cm)
Abscess size
0 to 4 cm
5 to 8 cm
>8 cm

TOA
Negative
Positive
(or not
N (%) documented)
N (%)
127 (94%)
3 days
22 (16%)
28 (21%)

8 (6%)
—
113 (84%)
107 (79%)

37 (27%)
109 (81%)
42 (31%)
29 (21%)
50 (37%)
36 (27%)
69 (51%)
65 (48%)
91 (67%)
11 (12%)
13 (14%)
106 (79%)
94 (70%)
3 (2%)
14.2 (5.9)

98 (73%)
26 (19%)
93 (69%)
106 (79%)
85 (63%)
99 (73%)
66 (49%)
70 (52%)
44 (33%)
77 (85%)
74 (81%)
29 (21%)
41 (30%)
132 (98%)
—

37 (27%)
46 (34%)
52 (39%)
89 (66%)

—
—
—
—

6.7 (2.7)

—

43 (32%)
69 (51%)
23 (17%)

—
—
—

∗ 87

patients (64%) had no information on HIV in medical record
not documented for 5 patients
† Information missing for 21 patients.
∗∗ WBC

size of the abscess. Women with large and small abscesses
were compared by duration of hospitalization, surgical
intervention, and complication rate. The initial antibiotic
regimens were categorized to include at least (1) cefoxitin
and doxycycline, (2) ciprofloxacin and metronidazole, (3)
gentamicin and clindamycin, and (4) others.
Descriptive statistics were calculated using mean, standard deviation, and percentages. Comparisons and associations were made using Chi-square or Fisher’s exact test
for categorical variables. T-tests were used for continuous
variables; nonparametric tests were used for data that
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Table 3: Outcomes and initial antibiotic regimen by abscess size.

# days hospitalized mean (SD)
# days febrile (>38.2)
N (%)
Requiring drainage/surgery
Drainage∗
Surgery
Number of antibiotics used, mean (SD)
Antibiotic regimen∗
Cefoxitin and doxycycline
Ciprofloxacin and Flagyl
Gentamicin and clindamycin
Other
Any complication
∗ P-value

All patients
(N = 135)
4.6 (3.6)
1.1 (1.8)

Abscess ≤8 cm
(N = 112)
4.4 (3.4)
1.10 (1.6)

Abscess >8 cm
(N = 23)
5.7 (4.2)
1.35 (2.5)

42 (31%)
11 (8%)
34 (25%)
2.8 (1.2)

32 (29%)
9 (8%)
26 (23%)
2.7 (1.2)

10 (43%)
2 (9%)
8 (35%)
3.1 (1.3)

.16
.31
.24
.20

57 (43%)
11 (8%)
18 (14%)
46 (35%)
18 (13%)

50 (45%)
7 (6%)
13 (12%)
39 (35%)
10 (9%)

7 (30%)
4 (17%)
5 (22%)
7 (30%)
8 (35%)

.14

P-value
.09
.65

<.01

estimated from Fisher’s exact test.

Table 4: Outcomes of surgery and drainage by initial antibiotic
regimen.
No surgery/
drainage
Cefoxitin/Doxycycline
52 (91%)
Ciprofloxacin/Flagyl
5 (45%)
Gentamicin/Clindamycin
9 (50%)
Other
27 (59%)

Surgery/
drainage
5 (9%)
5 (55%)
9 (50%)
19 (41%)

P-value
<.0001

were not normally distributed. Estimates of relative risk
were estimated using Poisson regression with robust error
variance. This approach results in an unbiased estimate
when a binary outcome is common (>10%) [9]. The power
calculations with an α error of 0.05 and β error of 0.20
found that the number of TOAs needed to evaluate was 121
assuming that 15% of cases would have TOA < 8 cm and
30% would have TOA > 8 cm. To achieve our target of 121
cases of TOA, we estimated that 370 charts would need to be
reviewed given the frequent misdiagnosis of PID. Statistical
analyses were conducted using SAS v. 9.2 (SAS Corporation,
Cary, NC).

3. Results
Of 373 charts reviewed, 135 patients were identified as having
a TOA while 218 patients were excluded based on the lack
of presence of an abscess. Demographic and reproductive
characteristics are provided in Table 1. The average age was
35.2 years (SD 10.0), and the mean gravidity and parity were
1.96 (SD 1.76) and 1.52 (SD 1.64), respectively. More than
two-thirds were black, and 10% gave a history of having had
a bilateral tubal ligation.
Clinical characteristics of the study population are noted
in Table 2. The most common reason for presentation was

pain (94%) with a median duration of 3 days. Only 27% of
patients had a fever on admission. The mean white blood
count (WBC) on admission was 14.2 (SD 5.9) with 27%
having WBC less than 10,000. Few subjects had positive tests
for N. gonorrhoeae (12%) and C. trachomatis (14%). Imaging
was obtained in most cases with patients frequently having
either a CT (79%) or an ultrasound (70%). MRI was used
in only 3 cases (2%). In the only case in which imaging
was not obtained, the TOA was diagnosed during her
cesarean section and bilateral tubal ligation and confirmed
on pathology. Abscess size ranged from 1.5 cm to 16 cm with
a mean of 6.7 cm. Most (51%) abscesses were between 5 and
8 cm. Two-thirds of abscesses were unilateral. Of patients
with bilateral abscesses, the maximal diameter of the smaller
abscess was 8 cm.
Comparison was made between those patients with
abscesses ≤8 cm or >8 cm (Table 3). Of the 135 patients with
a TOA, 112 (83%) had an abscess ≤8 cm and 23 (17%) had
an abscess >8 cm. Patients with larger abscesses averaged
longer duration of hospitalization, more complications,
longer duration febrile, and an increased need for surgery
or drainage when compared with those patients with smaller
abscesses. Every 1 cm increase in abscess size is associated
with an increase in hospitalization by 0.4 days (P = .001).
The mean abscess size for those requiring drainage or surgery
was 7.7 cm versus 6.3 cm (P = .02) for those with successful
conservative management. Among the larger abscess group, 7
hysterectomies (30%) were performed with 8 (35%) patients
receiving a simple adnexectomy. Patients with abscesses
≤8 cm had fewer complications (9%) than did patients with
abscesses >8 cm (35%, P < .01). Patients often had more than
one complication; 18 patients developed 35 complications.
The most common complication was blood transfusion
which occurred in 14 patients (10%). There were no
deaths. Patients with larger abscesses were febrile for longer
versus those with smaller abscesses (1.35 versus 1.10 days,
P = .65).
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Patients were then evaluated by initial antibiotic regimen
(Table 4). Fifty-seven patients were initially placed on regimens containing cefoxitin and doxycycline, and of these, 91%
were successfully managed conservatively. Patients placed
initially on regimens including cefoxitin and doxycycline
were less likely to require surgery or drainage. This is in
contrast to other antibiotic regimens which had approximate
equal need for surgery or drainage in the smaller and larger
abscess groups. A regression model was used to assess the
need for surgical intervention or drainage controlling for
other confounders. The relative risk for cefoxitin/doxycycline
regimen was 0.21 (95%, CI 0.09–0.48) adjusting for age
and total number of antibiotics. This finding persisted when
fever, abscess >8 cm, and days hospitalized were included in
the model.

4. Discussion
We found that TOA size is associated with important
outcomes including more complications and longer duration
of hospitalization as well as an increased need for surgery or
drainage when compared with those patients with smaller
abscesses. Reed et al. also found that increasing abscess size
is associated with increasing need for operative management
[8]. We found a 43% failure rate for abscesses >8 cm
while Reed showed a 35% failure rate for abscesses 7 to
9 cm and nearly 60% failure rate for abscesses ≥10 cm. In
contrast, Gjelland et al. noted that treatment success was
not aﬀected by the size of the abscess or the presence of
bilateral abscesses in a sample restricted to abscesses with
maximal diameter of at least 3 cm. The authors of this study
recommended transvaginal drainage as a first-line procedure
[10].
Originally, treatment of TOA was thought to require
bilateral oophorectomy and hysterectomy. Medical management with broad spectrum antibiotics is now generally
considered as the initial management for unruptured TOAs
[11]. However, optimal treatment of TOA remains unclear.
The 2006 Center for Disease Control and Prevention Sexually
Transmitted Diseases Treatment Guidelines recommends
inpatient intravenous antibiotics for at least 24 hours. No
specific inpatient antibiotic regimen is suggested. Upon
discontinuation of parenteral therapy, the CDC recommends that clindamycin or metronidazole be used with
doxycycline for a total of 14 days of treatment [12]. Sweet
recommends broad spectrum antibiotic coverage including
coverage of Gram-negative anaerobes for at least 24 hours
[11]. Oral therapy and hospital discharge are acceptable
when the patient has had a favorable clinical response to
therapy. Surgery or drainage should be considered when
the patient displays a failure to respond in 48 to 72 hours
[9].
Drainage procedures have been increasingly evaluated
in the management of TOA. Most recommendations for
the management of TOA advise drainage after conservative
management has failed [9]. However, several studies show
that early drainage of all TOAs is safe and improves outcomes
[10, 13] and may be appropriate as a primary therapy
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[14]. Drainage may be accomplished by CT or ultrasound
through the abdomen, vagina, rectum, or transgluteal.
Gjelland et al. observed in a retrospective review that, in
302 cases of transvaginal drainage of TOA combined with
antibiotics, 93% patients avoided surgery with no major
procedure-related complications [10]. Perez-Medina randomized 40 women to traditional conservative management
versus antibiotic therapy plus early transvaginal drainage in
unruptured TOAs and found that 90% had successful early
response versus 65% in the control group (P-value ≤ .05)
[15]. Moreover, they found that early transvaginal drainage
was associated with significantly shorter hospital stays and
decreased morbidity. Our study observed only 11 drainage
procedures that were split relatively equally between the 2
abscess groups and surgical drainage was not a primary
treatment. Thus, we could not assess the eﬀect of drainage
on length of hospitalization.
Regarding antibiotic regimens for TOA, Wiesenfeld and
Sweet summarized the response rates of TOAs to medical
therapy and showed a 72% success rate in patients treated
with clindamycin and aminoglycoside (n = 101) versus 82%
success rate in patients treated with cefoxitin or cefotetan and
doxycycline (n = 62) [6]. However, this finding has not been
consistently replicated in the literature; another study found
this regimen to be less successful [15]. Our data are consistent
with the review by Wiesenfeld and Sweet—we found that
9% of patients who were initially treated with cefoxitin and
doxycycline required surgical intervention or drainage. These
findings should be interpreted with caution, as many of the
patients started on the cefoxitin and doxycycline regimen
received additional antibiotics.
The strengths of our study are that we have a large
number of TOAs despite its being an infrequent outcome.
Management of TOA was specifically evaluated with emphasis on the influence of abscess size as a prognostic marker
of outcome. The limitations of our study include a relatively
small number of large TOAs and the inability to completely
control confounding variables such as disease severity. In
addition, our study design is unable to completely control
confounding factors that may influence the apparent success
rate of cefoxitin and doxycycline. Randomized trials are
needed to provide sound evidence regarding appropriate
antibiotic therapy for TOAs and whether routine drainage of
TOAs can decrease prolonged hospitalizations and improve
reproductive outcomes.
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